Upregulation of drug transporter expression by osteopontin in prostate cancer cellss

I. Shan Hsieh, Wei Hsun Huang, Houng Chi Liou, Woei-Jer Chuang, Rong Sen Yang, Wen Mei Fu

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Multidrug resistance is a major cause of chemotherapy failure. Recent studies indicate that drug resistance can be rapidly induced by some soluble factors, such as cytokines, chemokines, growth factors, and cell adhesion factors in the tumor microenvironment. Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-aspartic acid (RGD) domain for binding to integrin. Here we found OPN expression to be upregulated by hypoxic condition in PC-3 prostate tumor cells. OPN increased the mRNA and protein expression of pglycoprotein (P-gp), a subfamily of ATP-binding cassette transporter in a concentration- and time-dependent manner. The increase in P-gp transporter by OPN was mediated by binding to avb3 integrin. Daunomycin (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and OPN increased the drug pumping-out activity. OPN inhibited DUN-induced cell death, which was antagonized by avb3 monoclonal antibody. Long-term treatment with DUN further enhanced the expression of OPN. Knockdown of endogenous OPN potentiated the DUN-induced apoptosis of PC-3 cells. Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin- D, and rapamycin, which are also P-gp substrates. The animal studies also showed that OPN knockdown enhanced the cytotoxic action of DUN. These results indicate that OPN is a potential therapeutic target for cancer therapy to reduce drug resistance in sensitive tumors.

Original languageEnglish
Pages (from-to)968-977
Number of pages10
JournalMolecular Pharmacology
Volume83
Issue number5
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Osteopontin
Prostatic Neoplasms
Up-Regulation
Daunorubicin
Pharmaceutical Preparations
Drug Resistance
Integrins
Cell Death
Neoplasms
Tumor Microenvironment
ATP-Binding Cassette Transporters
Extracellular Matrix Proteins
Multiple Drug Resistance
Dactinomycin
Sirolimus
Paclitaxel
Chemokines
Aspartic Acid
Doxorubicin
Glycine

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Hsieh, I. Shan ; Huang, Wei Hsun ; Liou, Houng Chi ; Chuang, Woei-Jer ; Yang, Rong Sen ; Fu, Wen Mei. / Upregulation of drug transporter expression by osteopontin in prostate cancer cellss. In: Molecular Pharmacology. 2013 ; Vol. 83, No. 5. pp. 968-977.
@article{465f09d877474462a96ec8fbc3dd633e,
title = "Upregulation of drug transporter expression by osteopontin in prostate cancer cellss",
abstract = "Multidrug resistance is a major cause of chemotherapy failure. Recent studies indicate that drug resistance can be rapidly induced by some soluble factors, such as cytokines, chemokines, growth factors, and cell adhesion factors in the tumor microenvironment. Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-aspartic acid (RGD) domain for binding to integrin. Here we found OPN expression to be upregulated by hypoxic condition in PC-3 prostate tumor cells. OPN increased the mRNA and protein expression of pglycoprotein (P-gp), a subfamily of ATP-binding cassette transporter in a concentration- and time-dependent manner. The increase in P-gp transporter by OPN was mediated by binding to avb3 integrin. Daunomycin (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and OPN increased the drug pumping-out activity. OPN inhibited DUN-induced cell death, which was antagonized by avb3 monoclonal antibody. Long-term treatment with DUN further enhanced the expression of OPN. Knockdown of endogenous OPN potentiated the DUN-induced apoptosis of PC-3 cells. Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin- D, and rapamycin, which are also P-gp substrates. The animal studies also showed that OPN knockdown enhanced the cytotoxic action of DUN. These results indicate that OPN is a potential therapeutic target for cancer therapy to reduce drug resistance in sensitive tumors.",
author = "Hsieh, {I. Shan} and Huang, {Wei Hsun} and Liou, {Houng Chi} and Woei-Jer Chuang and Yang, {Rong Sen} and Fu, {Wen Mei}",
year = "2013",
month = "5",
day = "1",
doi = "10.1124/mol.112.082339",
language = "English",
volume = "83",
pages = "968--977",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

Upregulation of drug transporter expression by osteopontin in prostate cancer cellss. / Hsieh, I. Shan; Huang, Wei Hsun; Liou, Houng Chi; Chuang, Woei-Jer; Yang, Rong Sen; Fu, Wen Mei.

In: Molecular Pharmacology, Vol. 83, No. 5, 01.05.2013, p. 968-977.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Upregulation of drug transporter expression by osteopontin in prostate cancer cellss

AU - Hsieh, I. Shan

AU - Huang, Wei Hsun

AU - Liou, Houng Chi

AU - Chuang, Woei-Jer

AU - Yang, Rong Sen

AU - Fu, Wen Mei

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Multidrug resistance is a major cause of chemotherapy failure. Recent studies indicate that drug resistance can be rapidly induced by some soluble factors, such as cytokines, chemokines, growth factors, and cell adhesion factors in the tumor microenvironment. Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-aspartic acid (RGD) domain for binding to integrin. Here we found OPN expression to be upregulated by hypoxic condition in PC-3 prostate tumor cells. OPN increased the mRNA and protein expression of pglycoprotein (P-gp), a subfamily of ATP-binding cassette transporter in a concentration- and time-dependent manner. The increase in P-gp transporter by OPN was mediated by binding to avb3 integrin. Daunomycin (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and OPN increased the drug pumping-out activity. OPN inhibited DUN-induced cell death, which was antagonized by avb3 monoclonal antibody. Long-term treatment with DUN further enhanced the expression of OPN. Knockdown of endogenous OPN potentiated the DUN-induced apoptosis of PC-3 cells. Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin- D, and rapamycin, which are also P-gp substrates. The animal studies also showed that OPN knockdown enhanced the cytotoxic action of DUN. These results indicate that OPN is a potential therapeutic target for cancer therapy to reduce drug resistance in sensitive tumors.

AB - Multidrug resistance is a major cause of chemotherapy failure. Recent studies indicate that drug resistance can be rapidly induced by some soluble factors, such as cytokines, chemokines, growth factors, and cell adhesion factors in the tumor microenvironment. Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-aspartic acid (RGD) domain for binding to integrin. Here we found OPN expression to be upregulated by hypoxic condition in PC-3 prostate tumor cells. OPN increased the mRNA and protein expression of pglycoprotein (P-gp), a subfamily of ATP-binding cassette transporter in a concentration- and time-dependent manner. The increase in P-gp transporter by OPN was mediated by binding to avb3 integrin. Daunomycin (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and OPN increased the drug pumping-out activity. OPN inhibited DUN-induced cell death, which was antagonized by avb3 monoclonal antibody. Long-term treatment with DUN further enhanced the expression of OPN. Knockdown of endogenous OPN potentiated the DUN-induced apoptosis of PC-3 cells. Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin- D, and rapamycin, which are also P-gp substrates. The animal studies also showed that OPN knockdown enhanced the cytotoxic action of DUN. These results indicate that OPN is a potential therapeutic target for cancer therapy to reduce drug resistance in sensitive tumors.

UR - http://www.scopus.com/inward/record.url?scp=84876544010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876544010&partnerID=8YFLogxK

U2 - 10.1124/mol.112.082339

DO - 10.1124/mol.112.082339

M3 - Article

VL - 83

SP - 968

EP - 977

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -